Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy

Swetha Kambhampati, MD, City of Hope, Duarte, CA, describes the rationale and findings from a single-center retrospective study evaluating standard of care CAR-T therapy in patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL). Overall, the study demonstrated that both safety and efficacy outcomes were comparable to those observed in patients with de novo DLBCL, thereby suggesting CAR-T therapy is a promising option in this population of high unmet medical need. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.